MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.

Gene copy number analysis for some of the important molecules in lung tumorogenesis, such as MET, hepatocyte growth factor [(HGF), ligand for MET), epidermal growth factor receptor (EGFR), and paxillin (PXN), is likely to determine both the type of treatment and prognosis. Formalin-fixed paraffin-embedded (FFPE) archival tumor tissue samples are an excellent source for determining key molecular changes in the OncoGenome; however, existing extraction procedures yield relatively poor quality genomic DNA fragments. Although FISH is the method of choice for determining amplification of a gene, a more rapid quantitative poly-merase chain reaction (qPCR) technique to determine gene copy number can be used when reasonably good quality genomic DNA is available. We report here a relatively rapid method based on microwave/chelex-100 treatment that gives rise to genomic DNA fragments ranging from 1 to 12 Kb and beyond, thereby attesting to its superior quality. Genomic PCR for beta-globin gene gave reliable and reproducible results. The number of steps for extracting the DNA was kept to a minimum, and instead of precipitating the DNA, we preserved the genomic DNA extracts so as to prevent a loss in DNA yield. We found the extracts to be stable and amenable to qPCR and mutational analysis. Using lung adenocarcinoma FFPE samples and cell lines derived from lung adenocarcinomas, we demonstrated that the gene copy number for MET in lung adenocarcinoma tissue samples was preferentially increased over EGFR, HGF, and PXN and that it positively correlated with a better prognosis. In contrast, the genomic DNA extracted from 25 NSCLC cell lines gave a relatively higher gene copy number for all four genes evaluated. Our results indicate that the microwave/chelex-100-based method yields good-quality genomic DNA extracts that can be used for complex DNA analysis, such as determination of gene copy number. In addition, our data demonstrated that the adenocarcinoma cell lines potentially evolved under ex vivo conditions, and therefore, in genetic studies it is imperative to use primary tumors for generalized conclusions about lung tumors.

[1]  J. Stewart Lung carcinoma in African Americans , 2001, Cancer.

[2]  J. Christensen,et al.  Expression and mutational analysis of MET in human solid cancers , 2008, Genes, chromosomes & cancer.

[3]  M. Ranson,et al.  Where next for gefitinib in patients with lung cancer? , 2006, The Lancet. Oncology.

[4]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[5]  Stuart Schwartz,et al.  Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. , 2008, Cancer research.

[6]  B. Vogelstein,et al.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. , 1985, Biochemical and biophysical research communications.

[7]  Michael Worobey,et al.  The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues–Which Methods Are Useful When? , 2007, PloS one.

[8]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[9]  R. Sepp,et al.  Rapid techniques for DNA extraction from routinely processed archival tissue for use in PCR. , 1994, Journal of clinical pathology.

[10]  J. Primrose,et al.  Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. , 1999, Nucleic acids research.

[11]  R. Salgia,et al.  MET as a target for treatment of chest tumors. , 2009, Lung cancer.

[12]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[13]  Luca Toschi,et al.  Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer , 2008, Clinical Cancer Research.

[14]  M. Westerhoff,et al.  Protein kinase C beta in malignant pleural mesothelioma , 2008, Anti-cancer drugs.

[15]  R Higuchi,et al.  Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. , 2013, BioTechniques.

[16]  R. Salgia,et al.  EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC , 2008, TheScientificWorldJournal.

[17]  N. Saijo,et al.  Emerging ethnic differences in lung cancer therapy , 2008, British Journal of Cancer.

[18]  C. Taylor,et al.  Paraffin section immunocytochemistry for estrogen receptor: The time has come , 1996, Cancer.